France launches breast and ovarian cancer study:
This article was originally published in Clinica
A new study has been launched in France to monitor patients at risk of familial cancer. The study, established by the cancer and genetics group of the national anticancer federation, will monitor women who have a family history of breast and ovarian cancer. The group estimates that this represents some 5-10% of female cancer cases, who have on average a 50% chance of developing cancer by the age of 50 (2% of the general population). Almost 1,000 women will be monitored for two years.
You may also be interested in...
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.